Navigation Links
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Date:1/23/2013

add due to rounding2013 GuidanceFor the full year 2013, the Company expects:

  • Total revenues to be in the range of $17.8 billion to $18.2 billion and adjusted EPS to be in the range of $6.85 to $7.15.
  • Adjusted tax rate to be in the range of 14 percent to 15 percent. This reflects the impact of the foreign tax credit associated with the Puerto Rico excise tax. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2013 to be in the range of 17 percent to 18 percent.
  • Capital expenditures to be approximately $700 million.
  • Product and Pipeline Update

  • AMG 145:  The Company recently initiated Phase 3 studies in subjects with high levels of LDL cholesterol.
  • Trebananib (AMG 386):  Enrollment has resumed for the Phase 3 study in recurrent ovarian cancer that was previously suspended due to DOXIL® (doxorubicin HCl liposome injection) supply issues.
  • Aranesp:  The Company announced top-line results of the Phase 3 RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
  • deCODE Genetics:  The Company completed the acquisition of deCODE Genetics in December 2012.
  • Non-GAAP Financial Measures
    The Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the three and twelve months ended Dec. 31, 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions, cost-savings initiatives, various legal proceedings, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.

    Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP) basis and Free Cash Flow which is a non-GAAP financial measure for the three and twelve months ended Dec. 31, 2012 and
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
    3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
    4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
    6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
    8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
    9. Herborium Group Reports Record 6 Month Revenues
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)...  PANTHERx Specialty Pharmacy announced today that it ... a Washington, DC -based health ... the health care industry. Logo - ... accreditation process demonstrates a commitment to quality services ... processes through benchmarking organizations against nationally recognized standards. ...
    (Date:9/2/2014)... Actavis plc (NYSE: ACT ) ... (FDA) has accepted for filing Actavis, New Drug Application ... of diarrhea and abdominal pain in men and women ... for eluxadoline has been granted priority review status by ... "The NDA filing of eluxadoline marks an ...
    (Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation ... previously announced agreement to purchase the Interventional business ... of Boston Scientific to offer physicians and healthcare ... treat challenging vascular conditions. The addition ... innovative technologies supports the Boston Scientific strategy to ...
    Breaking Medicine Technology:PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
    (Date:9/2/2014)... 02, 2014 With recent expansions to their ... to create a consistent look or specific ambiance that tells ... floor you walk on and the chair you sit in, ... wood designs. , “We’re excited to offer a more ... It saves time, adds consistency, and let’s not forget celebrates ...
    (Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
    (Date:9/2/2014)... white pill may help scientists learn why patients with ... even if their lungs are relatively healthy. , ... Revatio to treat pulmonary hypertension and Viagra for erectile ... antioxidants will help them identify the root of the ... patients. , "We want to understand why these ...
    (Date:9/2/2014)... of opioid-involved overdoses has become an increasing concern to ... the New York City Department of Health and Mental ... 2011 was nearly triple the number of such deaths ... to a dramatic rise in nonmedical prescription opioid (PO) ... in heroin use among youth who transitioned from POs ...
    (Date:9/2/2014)... 2014In a new guideline, the Society for Maternal-Fetal Medicine ... in pregnancy. , "There is no evidence that ... of Delaware Center for Maternal and Fetal Medicine and ... is evidence that bed rest can be harmful for ... five women are placed on bed rest during their ...
    Breaking Medicine News(10 mins):Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2
    ... saves a life. Saturday, April 25 is World Malaria Day. , ... ... teaming up with the United Nations Foundation and its Nothing But Nets ... his New Look Foundation, Raymond and the UN Foundation will provide opportunities ...
    ... | About 400 cancer therapy specialists from 100 countries ... week in Vienna at an IAEA event to discuss modern ... Conference on Advances in Radiation Oncology (ICARO) will start on ... the Vienna International Center. , All sessions of the ...
    ... Medical Technologies, Inc. (Nasdaq: PMTI ), a leading ... hold its quarterly conference call of its 2009 first quarter ... Eastern Time. If you would like to participate, please call ... The telephone replay will be available one hour after the ...
    ... Addicts, even those who have been abstinent for long ... memories of prior drug use. For example, exposure to ... a contextual memory can increase their craving for the ... study in the April 15th issue of Biological Psychiatry ...
    ... CINCINNATI, April 23 Kendle (Nasdaq: KNDL ... quarter 2009 financial results after the market closes on ... telephone conference call and simultaneous webcast on Thursday, May ... answer session will follow.(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ...
    ... PALO ALTO, Calif., April 23 Percutaneous Systems, Inc. ... Accordion CoAx(TM) Stone Control Device, the newest member ... tools, at the upcoming annual meeting of the American ... Chicago, Illinois.The Accordion CoAx Stone Control Device is an ...
    Cached Medicine News:Health News:IAEA conference to focus on new techniques in cancer treatment 2Health News:Palomar Medical Technologies to Host First Quarter 2009 Financial Results Conference Call and Webcast on April 30, 2009 2Health News:Treating addiction by eliminating drug-associated memories 2Health News:Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 3
    ... DTX Series Multimode Detectors provide unmatched ... of application and automation needs. Capable ... measurements on the same instrument, the ... instruments or can be integrated seamlessly ...
    ... PCR, cDNA and Oligonucleotides The Tecan ... a variety applications that are quantified by Fluorescence, ... handle assays in Microplate formats from 6 ... Cuvettes Independent whether you have to ...
    ... Designed for Ultra High Throughput Screening ... assay detection performance. Allows for smooth ... assay development by sharing all the ... HT, fluorescence intensity, fluorescence polarization, time-resolved ...
    ... system used to detect and quantitate contaminants, ... cell protein, bovine contaminants (e.g., BSA, IgG, ... any unique protein that can be bound ... and plasmid copy number. The system reduces ...
    Medicine Products: